Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus

@article{Doucet2011EfficacyAS,
  title={Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus},
  author={J. Doucet and Ant{\^o}nio Roberto Chacra and Pierre Maheux and Jane Lu and Susan Harris and Julio Rosenstock},
  journal={Current Medical Research and Opinion},
  year={2011},
  volume={27},
  pages={863 - 869}
}
Abstract Objective: To assess the safety and efficacy of saxagliptin (5 mg once-daily) in older patients (≥65 years of age) with inadequately controlled type 2 diabetes. Research design and methods: In this retrospective subgroup analysis, data from five randomized, double-blind, placebo-controlled, multicenter, 24-week, phase 3 trials were included. The primary studies evaluated saxagliptin 5 mg once-daily (monotherapy or add-on) in patients aged 18–77 years with HbA1c ≥7.0% (four studies) or… 
Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus
TLDR
Saxagliptin was effective and well tolerated, with a low risk of hypoglycemia, when used as monotherapy, add-on therapy, or initial combination therapy with metformin in older patients with T2DM.
Saxagliptin efficacy and safety in patients with type 2 diabetes receiving concomitant statin therapy.
TLDR
Saxagliptin improves glycemic control and is generally well tolerated in patients with T2DM, irrespective of concomitant statin therapy.
Assessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials
TLDR
Saxagliptin versus control was associated with a reduction in glucagon area under the curve (AUC) from baseline and increases in insulin AUC, C-peptide A UC, and the homeostasis model assessment of β-cell function.
Efficacy and Safety of Saxagliptin in Older Participants in the SAVOR-TIMI 53 Trial
TLDR
The SAVOR-TIMI 53 trial supports the overall CV safety of saxagliptin in a robust number of elderly and very elderly participants, although the risk of heart failure hospitalization was increased irrespective of age category.
Long-term safety and tolerability of saxagliptin add-on therapy in older patients (aged ≥65 years) with type 2 diabetes
TLDR
Saxagliptin add-on therapy was generally well tolerated in older patients aged ≥65 years with type 2 diabetes mellitus, with a long-term safety profile similar to that of placebo.
Efficacy and safety of saxagliptin and metformin as initial combination therapy in patients with type 2 diabetes : a meta-analysis
Purpose: This meta-analysis was performed to evaluate the efficacy and safety of saxagliptin and metformin as initial combination therapy in patients with type 2 diabetes. Methods: A meta-analysis
Saxagliptin for the treatment of type 2 diabetes mellitus: Focus on recent studies
TLDR
Saxagliptin plus metformin was shown to be non-inferior to glipizide plus met formin in lowering glycated hemoglobin from base-line, with reduced body-weight and lower hypoglycemic risk.
Saxagliptin: a review of its use as combination therapy in the management of type 2 diabetes mellitus in the EU.
Saxagliptin (Onglyza™) is a dipeptidyl peptidase 4 inhibitor widely approved for the treatment of type 2 diabetes mellitus. In the EU, saxagliptin is indicated as combination therapy with metformin,
Effects of Glimepiride versus Saxagliptin on β-Cell Function and Hypoglycemia: A Post Hoc Analysis in Older Patients with Type 2 Diabetes Inadequately Controlled with Metformin.
TLDR
In patients with lower β-cell function, the addition of a sulfonylurea to a metformin regimen was associated with an increased risk for hypoglycemia compared with that in patients with higher β-cells, and these findings in older patients are especially relevant because morbidity associated with hypglycemia is higher in this age group.
Noninsulin treatment of type 2 diabetes mellitus in geriatric patients: a review.
TLDR
The selection of noninsulin treatments in older patients with T2DM should be individualized based on patient assessment and on careful evaluation of the potential benefits (glycemic and extraglycemic) and risks (ie, hypoglycemia, weight gain, cardiovascular risks).
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 26 REFERENCES
Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes
TLDR
Once-daily saxagliptin monotherapy for 24 weeks was generally well tolerated and demonstrated clinically meaningful reductions in key parameters of glycemic control vs. placebo.
Management of Type 2 Diabetes in Treatment-Naive Elderly Patients
TLDR
Vildagliptin monotherapy was effective and well tolerated in treatment-naive elderly patients and did not increase adverse events among older patients with mild renal impairment.
The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
TLDR
Saxagliptin once daily added to meetformin therapy was generally well tolerated and led to statistically significant improvements in glycemic indexes versus placebo added to metformin in patients with type 2 diabetes inadequately controlled with met formin alone.
Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone.
TLDR
Saxagliptin added to TzD provided statistically significant improvements in key parameters of glycemic control vs. TZD monotherapy and was generally well tolerated.
Risk factors and management of diabetes in elderly French patients.
TLDR
Complications and/or associated diseases were more frequent in this cohort of elderly diabetic patients compared with those in studies not based on clinical examinations, highlighting the inadequate management of such patients.
Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24‐week, double‐blind, randomized trial
TLDR
This study evaluated the efficacy and tolerability of the dipeptidyl peptidase‐4 inhibitor, vildagliptin, and metformin in drug‐naïve elderly patients with type 2 diabetes to demonstrate non‐inferiority of vildAGliptin vs. metform in glycated haemoglobin (HbA1c) reduction.
Management of Type 2 Diabetes Mellitus in the Elderly
TLDR
A conservative and stepwise approach to the treatment of the elderly patient with type 2 diabetes is suggested; treatment may be initiated with monotherapy, followed by early intervention with a combination of oral agents including a sulphonylurea as a foundation insulin secretagogue in addition to a supplemental insulin sensitiser.
Use of antidiabetic drugs in elderly patients.
TLDR
This review of the literature is to analyze the results of studies including diabetic patients aged 70 years and older, finding that use of insulin or insulin analogs is frequent and prescription should be adapted to achieve an acceptable balance between the risk of hypoglycaemia and therapeutic goals.
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
TLDR
In patients with type 2 diabetes the risk of diabetic complications was strongly associated with previous hyperglycaemia, with the lowest risk being in those with HbA1c values in the normal range (<6.0%).
Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial
TLDR
The study aim was to evaluate the efficacy and safety of initial combination therapy with saxagliptin or metformin monotherapy in treatment‐naïve patients with type 2 diabetes and inadequate glycaemic control.
...
1
2
3
...